Bausch Health Companies (BHC) $41 PT Reiterated At Mizuho After A Post Novartis Spin SOTP Analysis
Tweet Send to a Friend
Mizuho Securities analyst Irina Koffler reiterated a Buy rating and $41.00 price target on Bausch Health Companies (NYSE: BHC) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
